Skip to main content Accessibility help
×
Home

Transparency in practice: Evidence from ‘verification analyses’ issued by the Polish Agency for Health Technology Assessment in 2012–2015

Published online by Cambridge University Press:  08 January 2018


Piotr Ozierański
Affiliation:
Department of Social and Policy Sciences, University of Bath, Bath, UK
Olga Löblová
Affiliation:
Department of Sociology, University of Cambridge, Cambridge, UK
Natalia Nicholls
Affiliation:
Department of Social and Policy Sciences, University of Bath, Bath, UK
Marcell Csanádi
Affiliation:
Doctoral School of Pharmacological and Pharmaceutical Sciences, University of Pecs, Hungary Syreon Research Institute, Hungary
Zoltán Kaló
Affiliation:
Institute of Economics, Eötvös Loránd University, Hungary Syreon Research Institute, Hungary
Martin McKee
Affiliation:
London School of Hygiene and Tropical Medicine, London, UK
Lawrence King
Affiliation:
Department of Economics, University of Massachusetts, Amherst, MA, USA
Corresponding
E-mail address:

Abstract

Transparency is recognised to be a key underpinning of the work of health technology assessment (HTA) agencies, yet it has only recently become a subject of systematic inquiry. We contribute to this research field by considering the Polish Agency for Health Technology Assessment (AHTAPol). We situate the AHTAPol in a broader context by comparing it with the National Institute for Health and Care Excellence (NICE) in England. To this end, we analyse all 332 assessment reports, called verification analyses, that the AHTAPol issued from 2012 to 2015, and a stratified sample of 22 Evidence Review Group reports published by NICE in the same period. Overall, by increasingly presenting its key conclusions in assessment reports, the AHTAPol has reached the transparency standards set out by NICE in transparency of HTA outputs. The AHTAPol is more transparent than NICE in certain aspects of the HTA process, such as providing rationales for redacting assessment reports and providing summaries of expert opinions. Nevertheless, it is less transparent in other areas of the HTA process, such as including information on expert conflicts of interest. Our findings have important implications for understanding HTA in Poland and more broadly. We use them to formulate recommendations for policymakers.


Type
Articles
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below.

References

Bendor, J., Glazer, A. and Hammond, T. (2001), ‘Theories of delegation’, Annual Review of Political Science, 4(1): 235269.CrossRefGoogle Scholar
Bochenek, T., Kocot, E., Rodzinka, M., Godman, B., Maciejewska, K., Kamal, S. and Pilc, A. (2016), ‘The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland’, Expert Review of Pharmacoeconomics & Outcomes Research, 17: 385400.CrossRefGoogle ScholarPubMed
del Llano-Señarís, J. E. (2015), ‘What Health Technology Assessment System Do we Really Need? A Critical Review of the Current Situation of Health Technology Assessment in Five European Countries’, in J. E. Llano-Señarís and C. Campillo-Artero (eds), Health Technology Assessment and Health Policy Today: A Multifaceted View of their Unstable Crossroads, e-book: Springer International Publishing, 3750.Google Scholar
Drummond, M. F., Schwartz, J. S., Jönsson, B., Luce, B. R., Neumann, P. J., Siebert, U. and Sullivan, S. D. (2008), ‘Key principles for the improved conduct of health technology assessments for resource allocation decisions’, International Journal of Technology Assessment in Health Care, 24(3): 244258.CrossRefGoogle ScholarPubMed
European Union network for Health Technology Assessment (2017), ‘Mission, vision & values’. EUnetHTA, http://www.eunethta.eu/about-us/mission-vision-values [15 January 2017].Google Scholar
Franken, M., Le Polain, M., Cleemput, I. and Koopmanschap, M. (2012), ‘Similarities and differences between five European drug reimbursement systems’, International Journal of Technology Assessment in Health Care, 28(4): 349357.CrossRefGoogle ScholarPubMed
Gulácsi, L., Rotar, A. M., Niewada, M., Löblová, O., Rencz, F., Petrova, G., Boncz, I. and Klazinga, N. S. (2014), ‘Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria’, European Journal of Health Economics, 15(Suppl. 1): S13S25.CrossRefGoogle ScholarPubMed
Hailey, D. (2003), ‘Toward transparency in health technology assessment: a checklist for HTA reports’, International Journal of Technology Assessment in Health Care, 19(1): 17.CrossRefGoogle ScholarPubMed
INFARMA and IGFP (2014), ‘Letter to the AHTAPol President’, Warszawa’, http://www.farmacja-polska.org.pl/cms/uploads/dokumenty/C25314081411530.pdf [6 December 2017].Google Scholar
Inotai, A., Pékli, M., Jóna, G., Nagy, O., Remák, E. and Kaló, Z. (2012), ‘Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology’, BMC Health Services Research, 12(1): 332, https://doi.org/10.1186/1472-6963-12-332.CrossRefGoogle ScholarPubMed
Jakubiak, L. (2014), ‘Zaczernianie danych w analizach – co i jak ukryć – zdania są podzielone’. Rynek Aptek, 17th October, http://www.rynekaptek.pl/marketing-i-zarzadzanie/zaczernianie-danych-w-analizach-co-i-jak-ukryc-zdania-sa-podzielone,6098.html [6 December 2017].Google Scholar
Kaltenthaler, E., Papaioannou, D., Boland, A. and Dickson, R. (2011), ‘The National Institute for Health and Clinical Excellence single technology appraisal process: lessons from the first 4 years’, Value in Health, 14(8): 11581165.CrossRefGoogle ScholarPubMed
Kawalec, P. and Malinowski, K. P. (2016), ‘Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012–2014, a retrospective analysis’, Health Policy, 120(11): 12401248.CrossRefGoogle ScholarPubMed
Kawalec, P., Sagan, A., Stawowczyk, E., Kowalska-Bobko, I. and Mokrzycka, A. (2016), ‘Implementation of the 2011 Reimbursement Act in Poland: desired and undesired effects of the changes in reimbursement policy’, Health Policy, 120(4): 356361.CrossRefGoogle ScholarPubMed
Kolasa, K., Dziomdziora, M. and Fajutrao, L. (2011a), ‘What aspects of the health technology assessment process recommended by International Health Technology Assessment agencies received the most attention in Poland in 2008?’, International Journal of Technology Assessment in Health Care, 27(1): 8494.CrossRefGoogle ScholarPubMed
Kolasa, K., Schubert, S., Manca, A. and Hermanowski, T. (2011b), ‘A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland’, Health Policy, 102(2–3): 145151.CrossRefGoogle ScholarPubMed
Kolasa, K., Kalo, Z., Zah, V. and Dolezal, T. (2012), ‘Role of Health Technology Assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries’, Expert Review of Pharmacoeconomics and Outcomes Research, 12(3): 283287.CrossRefGoogle ScholarPubMed
Landwehr, C. and Böhm, K. (2014), ‘Strategic institutional design: two case studies of non-majoritarian agencies in health care priority-setting.’, Government and Opposition, 51(4): 632660.CrossRefGoogle Scholar
Law on Health Care Services Funded from Public Sources (2004), ‘Act of 27th August 2004 on Health Care Services Funded from Public Sources ‘(Ustawa z dnia 27 sierpnia 2004 r. o świadczeniach opieki zdrowotnej finansowanych ze środków publicznych)’.Google Scholar
Law on Protection of Personal Information (1997), ‘Act of 29th August 1997 on Protection of personal information (Ustawa z dnia 29 sierpnia 1997 r. o ochronie danych osobowych)’.Google Scholar
Law on Unfair Competition (1993), ‘Act of 16th of April 1993 on Unfair Competition (Ustawa z dn. 16 kwietnia 1993 r o zwalczaniu nieuczciwej konkurencji)’.Google Scholar
Llano-Señarís, J. E. (2015), ‘What Health Technology Assessment System Do we Really Need? A Critical Review of the Current Situation of Health Technology Assessment in Five European Countries’, in J. E. Llano-Señarís and C. Campillo-Artero (eds), Health Technology Assessment and Health Policy Today: A Multifaceted View of their Unstable Crossroads, e-book: Springer International Publishing, 109129.Google Scholar
Löblová, O. (2016), ‘Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe’, Health Economics, Policy and Law, 11(3): 253273.CrossRefGoogle Scholar
Meneu, R. (2015), ‘The Wisdom Tooth of Health Technology Assessment’, in J. E. Llano-Señarís and C. Campillo-Artero (eds), Health Technology Assessment and Health Policy Today: A Multifaceted View of their Unstable Crossroads, e-book: Springer International Publishing, 3750.Google Scholar
National Institute for Health and Care Excellence (NICE) (2009), ‘Guide to the single technology appraisal process’.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014), ‘Guide to the processes of technology appraisal’.Google Scholar
National Institute for Health and Care Excellence (NICE) (2017), ‘NICE technology appraisal guidance’, https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance [19 January 2017].Google Scholar
National Institute for Health and Care Excellence (NICE) (n.d.), ‘Agreement between the Association of the British Pharmaceutical Industry (ABPI) and the National Institute for Health and Clinical Excellence (NICE) on guidelines for the release of company data into the public domain during a health technology appraisal’.Google Scholar
Nizankowski, R. and Wilk, N. (2009), ‘From idealistic rookies to a regional leader: the history of Health Technology Assessment in Poland’, International Journal of Technology Assessment in Health Care, 25(Suppl. S1): 156162.CrossRefGoogle ScholarPubMed
Ordinance on Minimum Requirements (2012), ‘Ordinance of 2nd April 2012 on minimum requirements that have to be met analyses included in applications for reimbursement and setting official retail price and [applications for] increasing the official retail price of medicines, foodstuffs of special designation, medical devices that do not have an equivalent reimbursement in a given indication. (Rozporządzenie Ministra Zdrowia z dnia 2 kwietnia 2012 r. w sprawie minimalnych wymagań, jakie muszą spełniać analizy uwzględnione we wnioskach o objęcie refundacją i ustalenie urzędowej ceny zbytu oraz o podwyższenie urzędowej ceny zbytu leku, środka spożywczego specjalnego przeznaczenia żywieniowego, wyrobu medycznego, które nie mają odpowiednika refundowanego w danym wskazaniu)’.Google Scholar
Ozierański, P. and King, L. (2016), ‘The persistence of cliques in the post-communist state. The case of deniability in drug reimbursement policy in Poland’, The British Journal of Sociology, 67(2): 216241.CrossRefGoogle ScholarPubMed
Ozierański, P. and King, L. (2017), ‘Governing drug reimbursement policy in Poland: The role of the state, civil society, and the private sector’, Theory and Society, e-pub ahead of print, https://doi.org/10.1007/s11186-017-9300-8.CrossRefGoogle Scholar
Ozierański, P., McKee, M. and King, L. (2012a), ‘The politics of Health Technology Assessment in Poland’, Health Policy, 108(2–3): 178193.CrossRefGoogle ScholarPubMed
Ozierański, P., McKee, M. and King, L. (2012b), ‘Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?’, Health Economics, Policy and Law, 7(2): 175195.CrossRefGoogle ScholarPubMed
Panteli, D., Eckhardt, H., Nolting, A., Busse, R. and Kulig, M. (2015), ‘From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries’, Health Research Policy and Systems, 13(1): 39.CrossRefGoogle ScholarPubMed
Plisko, R. (n.d.), ‘Ograniczenia QALY w ocenie technologii stosowanych w stanach terminalnych’. HTA Consulting.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2007), ‘Wytyczne przeprowadzania Oceny Technologii Medycznych (HTA)’. Kraków-Warszawa.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2009), ‘Guidelines for conducting Health Technology Assessment (HTA), version 2.1’. Warsaw.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2012), ‘Komunikat w sprawie tajemnic ustawowo chronionych zawartych w Analizach Wnioskodawcy’. Warszawa.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2014), ‘Komunikat Dotyczący Zakreślania Informacji Stanowiących Tajemnicę Przedsiębiorstwa W Dokumentach Publikowanych W Biuletynie Informacji Publicznej Agencji’. Warszawa.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2015), ‘Zarządzenia Nr 28/2015 Prezesa Agencji Oceny Technologii Medycznych i Taryfikacji’. Warszawa.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2016), ‘Wytyczne oceny technologii medycznych (HTA, ang. Health Technology Assessment), wersja 3.0’. Warszawa.Google Scholar
Pollitt, C., Bathgate, K., Caulfield, J., Smullen, A. and Talbot, C. (2001), ‘Agency fever? Analysis of an international policy fashion’, Journal of Comparative Policy Analysis, 3(3): 271290.CrossRefGoogle Scholar
The Reimbursement Act (2011), ‘Act of 12th May 2011 on the reimbursement of medicines, foodstufs of special designation and medical products (Ustawa z dnia 12 maja 2011 r. o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych)’.Google Scholar
Sandman, L. and Gustavsson, E. (2016), ‘Beyond the black box approach to ethics!: comment on “expanded HTA: enhancing fairness and legitimacy”’, International Journal of Health Policy and Management, 5(6): 393394.CrossRefGoogle Scholar
Sorenson, C., Drummond, M. and Kanavos, P. (2008), Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union, Volume 11, Europe: WHO Regional Office.Google Scholar
Thatcher, M. (2002), ‘Regulation after delegation: independent regulatory agencies in Europe’, Journal of European Public Policy, 9(6): 954972.CrossRefGoogle Scholar
Velasco Garrido, M., Zentner, A. and Busse, R. (2008), ‘Health Systems, Health Policy and Health Technology Assessment’, in M. V. Garrido, F. B. Kristensen, C. P. Nielsen and R. Busse (eds), Health Teechnology Assessment and Health Ppolicy-Making in Europe. Current Status, Challenges and Potential, e-book: EUnetHTA and European Observatory of Health Systems and Policies, 5378.Google Scholar

Altmetric attention score


Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 146
Total number of PDF views: 121 *
View data table for this chart

* Views captured on Cambridge Core between 08th January 2018 - 5th December 2020. This data will be updated every 24 hours.

Hostname: page-component-b4dcdd7-nlmhz Total loading time: 0.288 Render date: 2020-12-05T06:36:27.246Z Query parameters: { "hasAccess": "0", "openAccess": "0", "isLogged": "0", "lang": "en" } Feature Flags last update: Sat Dec 05 2020 06:00:34 GMT+0000 (Coordinated Universal Time) Feature Flags: { "metrics": true, "metricsAbstractViews": false, "peerReview": true, "crossMark": true, "comments": true, "relatedCommentaries": true, "subject": true, "clr": false, "languageSwitch": true }

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Transparency in practice: Evidence from ‘verification analyses’ issued by the Polish Agency for Health Technology Assessment in 2012–2015
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Transparency in practice: Evidence from ‘verification analyses’ issued by the Polish Agency for Health Technology Assessment in 2012–2015
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Transparency in practice: Evidence from ‘verification analyses’ issued by the Polish Agency for Health Technology Assessment in 2012–2015
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *